# Novel 7SK non-coding RNA fusions in soft tissue sarcomas to tumorigenesis

> **NIH NIH R03** · ROSWELL PARK CANCER INSTITUTE CORP · 2021 · $84,100

## Abstract

PROJECT SUMMARY
Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin that are often characterized by diagnostic
fusion oncoproteins corresponding with tumor subtype. We have recently observed that STS also harbor a
significant number of non-coding RNA (ncRNA) fusions, with RN7SK (7SK) fusions being the most prominent.
7SK ncRNA fusions predominantly involve other RNA polymerase III transcripts, occur at specific 7SK
breakpoints which reflect known characteristics of secondary structure, and are enriched in primary tumors
over cell lines. Furthermore, the presence of 7SK fusions is associated with a unique gene expression
signature, independent of tumor subtype. This gene signature involves altered expression of transcriptional
networks linked to transcriptional regulation, splicing, and translation, known functions of 7SK and its fusion
partners. Along with the predicted secondary structure of ncRNA fusions, this suggests the potential for
significant disruption of normal 7SK regulatory function in these tumors. Our overall hypothesis is that 7SK
ncRNA fusions represent a common mechanism by which normal transcription regulation is disrupted in soft
tissue sarcomas, contributing to disease pathogenesis. This R03 grant has been designed to allow us to gather
essential preliminary data to understand the biological function of these ncRNA in STS and query the
prevalence of these ncRNA fusions in other tumor types. Two specific aims are proposed:
 • Specific Aim 1: To determine effects of 7SK fusions on gene expression and tumor growth
 • Specific Aim 2: To characterize the prevalence of ncRNA fusions in STS and normal mesenchymal
 cells and to extend these findings to other types of cancer and their normal counterparts
If successful, this study will lay a foundation for future work focused on understanding the biology of ncRNA
fusions in tumorigenesis.

## Key facts

- **NIH application ID:** 10201211
- **Project number:** 1R03CA246001-01A1
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** Joyce Ellen Ohm
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $84,100
- **Award type:** 1
- **Project period:** 2021-03-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10201211

## Citation

> US National Institutes of Health, RePORTER application 10201211, Novel 7SK non-coding RNA fusions in soft tissue sarcomas to tumorigenesis (1R03CA246001-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10201211. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*